CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
London, United Kingdom and 73 other locations
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS...
Phase 4
London, United Kingdom and 2 other locations
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
London, United Kingdom and 161 other locations
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS...
Phase 1
London, Greater London, United Kingdom
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
London, United Kingdom and 107 other locations
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple...
Phase 4
London, United Kingdom and 9 other locations
effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...
Phase 3
London, London, City Of, United Kingdom and 20 other locations
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data ...
Phase 2
London, United Kingdom
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
London, United Kingdom and 121 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
London, United Kingdom and 230 other locations
Clinical trials
Research sites
Resources
Legal